| Literature DB >> 31531686 |
Alexander Winkelmann1, Micha Löbermann2, Uwe K Zettl3,4.
Abstract
In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactivation (shingles, herpes zoster) pose a particular challenge for neurologists and physicians in everyday clinical practice. On the one hand the various immunotherapeutic agents for treatment of MS have differently expressed risks for VZV-associated infections and on the other hand the currently available vaccination strategies (dead vs. live vaccines, single vs. combination vaccines) require an individualized approach. Moreover, in addition to the optimal timing of vaccination during the course of MS, the appropriate vaccine and, where indicated, the use of antiviral drugs should be determined.Entities:
Keywords: Chickenpox; Disease-modifying drugs; Multiple sclerosis; Shingles; Vaccination
Year: 2019 PMID: 31531686 DOI: 10.1007/s00115-019-00806-x
Source DB: PubMed Journal: Nervenarzt ISSN: 0028-2804 Impact factor: 1.214